Nanexa ABFRA:40M +0.66%53 PB Ratio is 4.78 as of Jul. 12, 2026, which is 47% above its 10-year median of 3.25. GuruFocus rates FRA:40M with a GF Score™ of 53/100 and a GF Value™ of €0.17 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 925 Drug Manufacturers companies, Nanexa AB ranks worse than 83.68% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-12), Nanexa AB's share price is €0.306. Nanexa AB's Book Value per Share for the quarter that ended in Mar. 2026 was €0.06. Hence, Nanexa AB's PB Ratio of today is 4.78.
The historical rank and industry rank for Nanexa AB's PB Ratio or its related term are showing as below:
FRA:40M'
s PB Ratio Range Over the Past 10 Years
Min: 0.51 Med: 3.25 Max: 8.63
Current: 5.38
During the past 12 years, Nanexa AB's highest PB Ratio was 8.63. The lowest was 0.51. And the median was 3.25.
FRA:40M's PB Ratio is ranked worse than 83.68% of 925
companies
in the Drug Manufacturers industry
Industry Median: 1.91
vs FRA:40M: 5.38
During the past 12 months, Nanexa AB's average Book Value Per Share Growth Rate was 14.70% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -33.80% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -28.90% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -7.60% per year.
During the past 12 years, the highest 3-Year average Book Value Per Share Growth Rate of Nanexa AB was 31.00% per year. The lowest was -44.00% per year. And the median was -5.70% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Nanexa AB PB Ratio Related Terms
Nanexa AB PB Ratio Historical Data
* Premium members only.
The historical data trend for Nanexa AB's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Nanexa AB's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nanexa AB PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Nanexa AB's PB Ratio distribution charts can be found below:
* The bar in red indicates where Nanexa AB's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Nanexa AB's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Nanexa AB (FRA:40M) has a PB Ratio of 4.78 as of Jul. 12, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Nanexa AB and its competitors. This is 47% above median its historical median of 3.25. Over the past decade, Nanexa AB's PB Ratio has ranged from 0.51 to 8.63. According to the industry distribution chart, Nanexa AB ranks #774 out of 925 companies in the Drug Manufacturers industry, placing it in the top 83.7%.
Is Nanexa AB's PB Ratio too high?
Nanexa AB's current PB Ratio of 4.78 is 47% above median its 10-year median of 3.25. Over the past 10 years, this metric has ranged from a low of 0.51 to a high of 8.63. The Drug Manufacturers industry median PB Ratio is 1.91. Nanexa AB's value of 4.78 is 150.3% above this industry median. Based on the distribution chart, Nanexa AB ranks #774 out of 925 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Nanexa AB has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Nanexa AB's PB Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Nanexa AB ranks #774 out of 925 companies for PB Ratio. This places Nanexa AB in the lower half of its industry. The industry median PB Ratio is 1.91. Nanexa AB's value of 4.78 is 150.3% above this benchmark. Historically, Nanexa AB's own PB Ratio has ranged from 0.51 to 8.63 over the past decade. While the company's 10-year median is 3.25 vs. the industry median of 1.91, Nanexa AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.91, based on 925 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nanexa AB's current PB Ratio of 4.78 is 150.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Nanexa AB and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nanexa AB's current PB Ratio is 4.78, which is 47% above median its own 10-year median of 3.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanexa AB stock overvalued right now?
Based on GuruFocus' analysis, Nanexa AB (FRA:40M) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.17, compared to a current price of €0.31 — trading 80% above its estimated fair value. The current PB Ratio is 4.78, which is 47% above median its 10-year median of 3.25 and 150.3% above the Drug Manufacturers industry median of 1.91. Nanexa AB's overall GF Score™ is 53/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Nanexa AB (FRA:40M), the current PB Ratio is 4.78 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nanexa AB (FRA:40M) Overvalued in 2026?
Based on GuruFocus' analysis, Nanexa AB stock appears to be overvalued.
The current stock price of €0.31 is trading 80% above its estimated GF Value™ of €0.17.
GuruFocus considers Nanexa AB to be Significantly Overvalued.
Key valuation signals for FRA:40M:
PB Ratio: 4.78 (47% above median its 10-year median of 3.25)
GF Value™: €0.17 vs. price of €0.31 (80% above fair value)
Industry Position: 150.3% above the Drug Manufacturers median (#774 of 925)
No single metric tells the full story. See the FRA:40M stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nanexa AB is a pharmaceutical company developing injectable drug products based on the proprietary drug delivery system PharmaShell - the high drug load delivery system enabling the next generation long-acting injectables through atomic layer precision. The company develops its products and also has collaboration agreements with several pharma companies, among others AstraZeneca. Geographically, the company derives maximum revenue from Nordic countries, while it also has its presence in Europe (excluding the Nordic countries), North America, and Asia.
53GF Score
Get the complete analysis for FRA:40M
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:40M has been successfully added to your 
